rethinkTHC Search
Menu
Study breakdown

Integrated therapy plus AI-enhanced contingency management shows promise for treating cannabis use disorder with co-occurring mental health conditions

Systematic ReviewModerate evidence
The takeaway

A systematic review of 38 studies found that integrated CBT approaches improved both psychiatric symptoms and cannabis use, while emerging AI tools for contingency management showed potential to personalize treatment and predict relapse.

Addiction treatment providers, digital health developers, clinical psychologists, PTSD treatment researchers

38 studies reviewed; integrated CBT improved both psychiatric symptoms and cannabis use

What the researchers found

Integrated cognitive-behavioral therapies improved psychiatric symptoms and reduced cannabis use, particularly for co-occurring depression and PTSD. Pharmacotherapies showed inconsistent benefits. ADHD-focused behavioral and stimulant approaches demonstrated promising cannabis use reductions. AI applications including machine-learning relapse prediction, remote contingency management delivery, and reinforcement-learning-based incentive optimization improved attendance and abstinence verification.

Why it matters

Cannabis use disorder rarely exists in isolation. Most people with CUD have co-occurring mental health conditions, and treating one without the other typically produces poor outcomes. This review maps the evidence for integrated approaches and points toward AI as a practical way to scale personalized treatment.

The numbers in context

38 studies met inclusion criteria. Co-occurring conditions examined: depression, PTSD, anxiety, ADHD. AI applications included smartphone/sensor-based relapse prediction, remote CM delivery, and reinforcement-learning incentive optimization.

How the study worked

Systematic search of PubMed, PsycINFO, Embase, and Web of Science through October 2025. Included clinical studies and systematic reviews on tailored interventions for CUD with co-occurring depression, PTSD, anxiety, or ADHD, plus research on AI-driven contingency management. 38 studies met inclusion criteria.

What this study cannot tell us

Systematic review format synthesizes heterogeneous studies. AI-enhanced contingency management research is still early-stage with small samples. Pharmacotherapy findings were inconsistent across studies. Publication bias possible.

How to read the evidence

Systematic review with comprehensive search strategy across four databases, but the included AI-enhanced CM studies are early-stage and heterogeneous.

When this study was published

2026 publication with literature search through October 2025

The bigger picture

The convergence of integrated psychotherapy and AI-powered treatment tools could transform CUD care from one-size-fits-all to genuinely personalized, addressing the dual challenge of psychiatric complexity and treatment scalability.

Questions still open

  • How quickly will AI-enhanced contingency management move from research to clinical practice? Can these integrated approaches be delivered in low-resource settings? Which co-occurring conditions respond best to integrated versus sequential treatment?

Common questions

What is contingency management?
A behavioral treatment that provides tangible rewards (like gift cards or vouchers) for meeting treatment goals such as negative drug tests. It is one of the most effective evidence-based treatments for substance use disorders.
How can AI help with addiction treatment?
AI can predict when someone is at risk of relapse using smartphone and sensor data, deliver remote treatment verification, and optimize reward schedules to keep people engaged in treatment.

Read the original research

Tailored psychotherapy and AI-enhanced contingency management for co-occurring disorders in cannabis use disorder: a systematic review.

Journal of addictive diseases, 1-14

Citation

Mishra, Sidharth; Mishra, Sayali; Rath, Sibanarayan. (2026). Tailored psychotherapy and AI-enhanced contingency management for co-occurring disorders in cannabis use disorder: a systematic review.. Journal of addictive diseases, 1-14. https://doi.org/10.1080/10550887.2026.2616726

Explore the wider topic